2024
Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars
Flores V, Sahin C, Taylor H. Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars. F&S Science 2024, 6: 65-72. PMID: 39393571, DOI: 10.1016/j.xfss.2024.10.004.Peer-Reviewed Original ResearchProgestin-based therapyAggressive forms of endometriosisPR lesionsProgesterone receptorGnRH antagonistMedroxyprogesterone acetatePR statusEndometriotic lesionsAggressive formResponse to MPAResponse to medical therapyPost-treatment sizeProgesterone receptor statusHuman endometriotic lesionsResponse to progestinsChronic gynecological diseaseDaily subcutaneous injectionsReproductive-age womenMouse xenograft modelResponse to medicationEndometrioma lesionsReceptor statusHormone suppressionPR expressionClinical response
2008
Leptin reverses weight loss–induced changes in regional neural activity responses to visual food stimuli
Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J. Leptin reverses weight loss–induced changes in regional neural activity responses to visual food stimuli. Journal Of Clinical Investigation 2008, 118: 2583-2591. PMID: 18568078, PMCID: PMC2430499, DOI: 10.1172/jci35055.Peer-Reviewed Original ResearchConceptsMiddle frontal gyrusNeural activityFood cuesFrontal gyrusFood-related visual cuesWeight lossFood intakeWeight loss-induced changesVisual food cuesVisual food stimuliMiddle temporal gyrusRelative leptin deficiencyWeight-reduced stateDaily subcutaneous injectionsBody weight maintenanceCognitive controlFood stimuliTemporal gyrusVisual cuesLeptin deficiencyObese subjectsWeight maintenanceLingual gyrusClinical managementFunctional MRI
2006
Patient willingness to take teriparatide
Fraenkel L, Gulanski B, Wittink D. Patient willingness to take teriparatide. Patient Education And Counseling 2006, 65: 237-244. PMID: 16965888, PMCID: PMC1769517, DOI: 10.1016/j.pec.2006.08.004.Peer-Reviewed Original ResearchMeSH KeywordsAbsorptiometry, PhotonAdministration, OralAgedAged, 80 and overBone Density Conservation AgentsChoice BehaviorConnecticutDrug Administration ScheduleFemaleFractures, BoneHealth Knowledge, Attitudes, PracticeHealth Services Needs and DemandHumansInjections, SubcutaneousMiddle AgedMultivariate AnalysisOsteoporosis, PostmenopausalPatient Acceptance of Health CarePostmenopauseRisk AssessmentSocioeconomic FactorsSurveys and QuestionnairesTeriparatideWomenConceptsDaily subcutaneous injectionsTreatment preferencesSubcutaneous injectionFuture fracturesMost womenAbsolute fracture riskTreatment of osteoporosisNovel treatment approachesConjoint analysis questionnairePostmenopausal womenAdaptive conjoint analysis questionnaireDaily injectionsPoor adherenceEfficacy advantageFracture riskPatients' willingnessClinical studiesAge 71Bone densitometryEffective treatmentNumber of subjectsTreatment approachesT-scoreOlder adultsWomen
2000
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years
Johnson K, Brooks B, Ford C, Goodman A, Guarnaccia J, Lisak R, Myers L, Panitch H, Pruitt A, Rose J, Kachuck N, Wolinsky J. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Multiple Sclerosis Journal 2000, 6: 255-266. PMID: 10962546, DOI: 10.1177/135245850000600407.Peer-Reviewed Original ResearchConceptsExpanded Disability Status ScaleOpen-label phaseOpen-label studyAccumulation of disabilityDaily subcutaneous injectionsGlatiramer acetateRelapse rateMultiple sclerosisSubcutaneous injectionRelapsing-remitting multiple sclerosisMean annual relapse rateDouble-blind cohortDouble-blind phaseSustained clinical benefitDouble-blind studyDisability Status ScaleAnnual relapse rateMultiple sclerosis patientsSclerosis patientsClinical benefitStatus ScaleSustained efficacyPatientsActive drugGlatiramer
1999
A Pharmacokinetic/Pharmacodynamic Model for Recombinant Human Growth Hormone Effects on Induction of Insulin-Like Growth Factor I in Monkeys 1
Sun Y, Lee H, Almon R, Jusko W. A Pharmacokinetic/Pharmacodynamic Model for Recombinant Human Growth Hormone Effects on Induction of Insulin-Like Growth Factor I in Monkeys 1. Journal Of Pharmacology And Experimental Therapeutics 1999, 289: 1523-1532. PMID: 10336548, DOI: 10.1016/s0022-3565(24)38301-6.Peer-Reviewed Original ResearchConceptsRecombinant human growth hormoneIGF-I inductionInduction of insulin-like growth factor-IInsulin-like growth factor-IGrowth factor-IIGF-IGroup BGroup ARhGH treatment groupOsmotic pumpRhGH effectHuman growth hormones’ effectsSustained-release microsphere formulationPharmacokinetic/Pharmacodynamic ModelFactor IGroup CIGF-I productionImplanted osmotic pumpDaily subcutaneous injectionsZero-order inputOsmotic pump deliveryHuman growth hormoneIndirect response modelShort-term i.Two-compartment model
1998
Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma.
Teicher BA, Williams JI, Takeuchi H, Ara G, Herbst RS, Buxton D. Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Research 1998, 18: 2567-73. PMID: 9703911.Peer-Reviewed Original ResearchMeSH Keywords9,10-Dimethyl-1,2-benzanthraceneAnimalsAnticarcinogenic AgentsAntineoplastic AgentsCarcinoma, Lewis LungCell DivisionCholestanolsCisplatinCombined Modality TherapyCyclophosphamideDoxorubicinDrug Therapy, CombinationFemaleFluorouracilMammary Neoplasms, ExperimentalMiceOxygenOxygen ConsumptionPaclitaxelPartial PressureRatsRats, Inbred F344ConceptsLewis lung carcinomaTumor growth delayPost-tumor implantationLung carcinomaGrowth delayLung metastasesTumor implantationMammary carcinomaTumor oxygenationDay 4Chemotherapeutic agentsPrimary Lewis lung tumorMurine Lewis lung carcinomaDaily subcutaneous injectionsLewis lung tumorTumor-bearing animalsModest effectCombination therapyContinuous infusionCytotoxic therapySystemic diseaseSubcutaneous injectionLung tumorsAntiangiogenic agentsHypoxic fraction
1992
Synthetic parathyroid hormone-like protein (1–74) is anabolic for bone in vivo
Weir E, Terwilliger G, Sartori L, Insogna K. Synthetic parathyroid hormone-like protein (1–74) is anabolic for bone in vivo. Calcified Tissue International 1992, 51: 30-34. PMID: 1393774, DOI: 10.1007/bf00296214.Peer-Reviewed Original ResearchConceptsBovine parathyroid hormoneSerum calciumParathyroid hormone-like proteinDaily subcutaneous injectionsPotent bone-resorbing agentHormone-related proteinDose-dependent increaseDry bone weightHighest dose levelHormone-like proteinBone-resorbing agentsBone dry weightLow dosage levelsHumoral hypercalcemiaParathyroid hormoneDihydroxyvitamin DMale SpragueDawley ratsSubcutaneous injectionHuman PTHrPBone calciumAnabolic agentsPTHrP actionDose levelsHigh doses
1989
Hepatic immunohistochemical localization of the tight junction protein ZO-1 in rat models of cholestasis.
Anderson J, Glade J, Stevenson B, Boyer J, Mooseker M. Hepatic immunohistochemical localization of the tight junction protein ZO-1 in rat models of cholestasis. American Journal Of Pathology 1989, 134: 1055-62. PMID: 2719075, PMCID: PMC1879891.Peer-Reviewed Original ResearchConceptsZO-1 proteinZO-1Tight junctionsConsecutive daily subcutaneous injectionsFrozen sectionsReflux of bileDaily subcutaneous injectionsBile duct obstructionCommon bile ductMale Sprague-DawleyHepatocyte tight junctionsBile duct ligation resultsTight junction protein ZO-1Cholestatic modelsDuct obstructionBile ductSubcutaneous injectionCholestatic liverRat modelEthinyl estradiolSprague-DawleyProtein ZO-1Immunoperoxidase stainingZO-1 stainingImmunohistochemical localization
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply